SynthesisBritish journal of haematology2010
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Synthesis in British journal of haematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Clinical pharmacokinetic characteristics and the food effect of radotinib.Investigational new drugs · 2026Trial
- Trial
- Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.International journal of hematology · 2019Trial
- Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.Haematologica · 2019Trial
- Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).European journal of haematology · 2015Trial
- Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing.Haematologica · 2026Review
- Real-world evidence for repurposing hydralazine as a potential epigenetic modulator for psoriasis: a 16-year retrospective nationwide cohort study.Journal of translational medicine · 2025Article
- Article
- Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.Pharmaceutics · 2020Article
- Is There a Role for Dose Modification of TKI Therapy in CML?Current hematologic malignancy reports · 2019Review
- Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders.Journal of clinical medicine · 2019Article
- Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.American journal of hematology · 2019Observational
- Review
- The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.Blood advances · 2017Article
- Article
- Review
- The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.Journal of cancer research and clinical oncology · 2014Article
- Adherence to BCR-ABL inhibitors: issues for CML therapy.Clinical lymphoma, myeloma & leukemia · 2012Review
- Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Cancer management and research · 2011Article
- Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy.Clinical Medicine Insights. Oncology · 2010Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
Second (2nd)-generation tyrosine kinase inhibitors (TKI) (dasatinib, nilotinib) are effective in patients with all phases of chronic myeloid leukaemia (CML). Dose reductions and treatment interruptions are frequently required due to toxicity, but their significance is unknown. We analysed the impact of dose reductions/interruptions and dose intensity of 2nd-generation TKI on response and survival. A total of 280 patients with CML (all phases) were analysed. Dose reductions were considered when the daily dose was below the standard dose. Dose intensity was determined based on the percentage of the ideal dose intensity. Overall, 176 patients (63%) required treatment interruptions and/or dose reduction at least once during therapy. Dose reductions/interruptions, analysed as a time-dependent covariate, were associated with worse failure-free survival only in patients with untreated CML. Dose intensity analysis did not reveal a worse response or survival in patients who received a lower dose intensity (<100%) during therapy or during the first 6 months. In conclusion, dose reductions and treatment interruptions of 2nd generation TKI in patients with CML have a minimal impact in the response rate and survival of these patients. Further studies are required to determine whether there might be a minimum adequate dose of these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.